Gilead Acquisition of Forty Seven Inc Tops SPT Week in Review

5. CAR T-Cell Therapy Improves Quality of Life for Adult Patients with Lymphoma

A study offers evidence that chimeric antigen receptor T-cell therapy may not only extend patients’ survival, but also improve their quality of life after treatment. Read more.

4. FDA Grants Fast Track Designation to Therapy for Recurrent or Metastatic Adenoid Cystic Carcinoma

AL101 is a potent, selective, injectable small molecule gamma secretase inhibitor and was granted Orphan Drug designation in May 2019 for the treatment of recurrent or metastatic adenoid cystic carcinoma. Read more.

3. Prioritizing Patient Access to Specialty Drugs: The Best of Both Worlds

Specialty pharmacies can provide seamless support across specialty mail and retail channels. Read more.

2. Evidence: Vital but Seldom Used Consistently by Payers

Peer-reviewed research conducted by the National Pharmaceutical Council and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center over the past 2 years sheds some light on what’s behind the discrepancies in coverage decisions from one insurer to the next. Read more.

1. Gilead Sciences Buys Immuno-Oncology Company Forty Seven Inc

Gilead has agreed to pay $95.50 per share in cash for Forty Seven Inc, adding the 5-year old biotechnology company to bolster its portfolio of oncology drugs. Read more.